A1H.F Amoeba SA
- Market cap
- EUR 31.5M
- P/E
- -
- P/B
- 7.64x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is A1H.F undervalued?
Graham numberThe Graham number of Amoeba SA cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Amoeba SA fundamental analysis
No fundamental analysis for Amoeba SA yet.
Amoeba SA stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Amoeba SA
Amoéba S.A. develops biological products and services for the treatment of microbiological risk in the sectors of water, health, and plant protection in France. The company has developed technology to treat water, surfaces, and chronic wounds that uses the natural biocidal capacity of the living amoeba Willaertia magna C2c Maky; and agriculture biocontrol technology for the treatment of phytopathogenic microorganisms using the lysed. Amoéba S.A. was incorporated in 2010 and …
Full company profileAmoeba SA financial statements
Amoeba SA annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -767K | -1.11M | -1.71M | -1.48M | -2.57M |
| Operating Income | -5.58M | -5.84M | -6.64M | -5.66M | -6.78M |
| EBITDA | - | -5.30M | -13.1M | -4.89M | -5.84M |
| Net Income | -7.82M | -8.02M | -14.3M | -6.59M | -8.30M |
| EPS | -0.38 | -0.17 | -0.29 | -0.13 | -0.12 |
| Balance Sheet | |||||
| Total Assets | 14.5M | 12.4M | 6.29M | 5.65M | 10.1M |
| Total Liabilities | 14.3M | 4.23M | 10.2M | 16.1M | 15.5M |
| Shareholders' Equity | 214K | 8.18M | -3.94M | -10.4M | -5.36M |
| Cash & Short-term Investments | 7.28M | 5.53M | 519K | 459K | 4.72M |
| Cash Flow | |||||
| Operating Cash Flow | -4.26M | -4.43M | -6.50M | -4.22M | -6.09M |
| Capital Expenditure | 145K | 306K | 6.08M | 565K | 862K |
| Free Cash Flow | -4.40M | -4.73M | -12.6M | -4.78M | -6.95M |
| Ratios | |||||
| ROE | -3,658.3% | -98.1% | - | - | - |
| ROA | -53.9% | -64.7% | -227.4% | -116.6% | -81.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
Amoeba SA dividends
Amoeba SA has not paid dividends in the last 5 fiscal years.
Who owns Amoeba SA
- Insiders 13.78%
- Institutions 0.40%
- Public & others 85.83%
- Shares outstanding 129M
- Free float 68.9M
Amoeba SA company profile
- Company name
- Amoeba SA
- Ticker
- A1H.F
- ISIN
- FR0011051598
- Exchange
- Frankfurt Exchange
- Sector
- Basic Materials
- Industry
- Agricultural Inputs
- Employees
- 23
- Fiscal year end
- December
- Address
- 38 Avenue des FrEres Montgolfier, Chassieu, France, 69680
- Phone
- 33 4 26 69 16 00
- Website
- amoeba-nature.com
About Amoeba SA
Amoéba S.A. develops biological products and services for the treatment of microbiological risk in the sectors of water, health, and plant protection in France. The company has developed technology to treat water, surfaces, and chronic wounds that uses the natural biocidal capacity of the living amoeba Willaertia magna C2c Maky; and agriculture biocontrol technology for the treatment of phytopathogenic microorganisms using the lysed. Amoéba S.A. was incorporated in 2010 and is headquartered in Chassieu, France.
Amoeba SA management
3- Mr. Jean-Francois DoucetGeneral Director
- Mr. Jean-Marc PetatMD of Green 4 Agro & Director · born 1964
- Dr. Sandrine TroussieuxScientific Director